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Objective. For the inflammation characteristic of
rheumatoid arthritis, the relative contribution of medi-
ators produced locally in the synovium versus those
circulating systemically is unknown. Complement factor
C3 is made in rheumatoid synovium and has been
proposed to be a crucial driver of inflammation. The
aim of this study was to test, in a mouse model of
rheumatoid arthritis, whether C3 synthesized within the
synovium is important in promoting inflammation.
Methods. Radiation bone marrow chimeras be-
tween normal and C3
/ mice were constructed in order
to generate animals that expressed or lacked expression
of C3 only in hematopoietic cells. Parabiotic mice were
made by surgically linking C3
/ mice to irradiated
wild-type mice to obtain animals having C3 only in the
circulation. Arthritis was induced by injection of serum
from arthritic K/BxN mice.
Results. In bone marrow chimeras, synthesis of
C3 by radioresistant cells was necessary and sufficient
to confer susceptibility to serum-transferred arthritis.
Parabionts having C3 only in the circulation remained
sensitive to arthritis induction, and the cartilage of
these arthritic mice contained deposits of C3.
Conclusion. In a mouse model in which the alter-
native pathway of complement activation is critical to
the induction of arthritis by autoantibodies, circulating
C3 was necessary and sufficient for arthritis induction.
The complement cascade is essential for the
induction of inflammatory arthritis by autoantibodies in
at least 2 mouse models (1–3). The role of complement
in human rheumatoid arthritis (RA) has been more
difficult to assess, but a contribution of this pathway is
suggested by several findings. First, complement compo-
nents are depleted (4,5) and complement degradation
products are generated (6,7) in the synovial fluid in RA
but not other types of inflammatory arthritis. Second, C3
is deposited on the surface of cartilage and synovium in
RA (8,9), as it is in various rodent models (10–12).
The details of complement involvement are par-
ticularly clear in the K/BxN mouse serum-transfer
model. K/BxN mice uniformly develop severe, symmet-
ric, inflammatory arthritis due to activation of the KRN
transgene-encoded T cell receptor by a peptide from the
glycolytic enzyme glucose-6-phosphate isomerase (GPI)
presented by the class II major histocompatibility com-
plex molecule A
g7 (13), leading to massive production of
anti-GPI antibodies. These antibodies can effectively
induce arthritis upon transfer into other mice (14).
Because a wide range of natural mutant and gene-
disrupted mouse strains can be used as recipients, this
serum-transfer model has allowed the delineation of
many genes and cell types required downstream of
autoantibody production (1,15–18). With regard to the
complement cascade, factors B, D (Monach PA: unpub-
lished observations), C3, C5, and the receptor for C5a
(C5aR) are required, whereas C1q, C4, C6, and the
complement receptors CR1, CR2, and CR3 are not
(1,19). Thus, induction of arthritis requires the alterna-
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2968tive pathway of complement activation, leading to pro-
duction of the chemoattractant and activating mediator
C5a. Recently, a similar requirement for alternative but
not classical pathway elements was found for induction
of arthritis by antibodies directed against type II colla-
gen (20). Most studies of complement in RA have not
differentiated between activation of the classical and
alternative pathways, but one that did so indicated that
local activation of the alternative pathway in synovial
fluid is particularly characteristic of RA (21).
The details of C3 involvement in inflammatory
arthritis are of particular interest, not only because this
protein is involved in all of the major pathways of
complement activation and subsequent activation of
effector mechanisms, but also because both systemic and
local synthesis have been well documented. A few years
ago, one might have assumed that the obligatory source
of C3 and other essential complement components
would be the liver. The liver is thought to be the source
of the vast majority of circulating C3, and although this
protein has a relatively short half-life, its concentration
in plasma is the highest of any complement protein, at
1.0–1.4 mg/ml. However, not only has the synthesis of
complement proteins by leukocytes now been clearly
demonstrated (22–24), but leukocyte-derived C3 was
found to be sufficient for the generation of antibody
responses to a model antigen (25) and to be both
necessary and sufficient for optimal antibody responses
to intradermal herpes simplex virus infection in mice
(26,27). Production of C3 by the inflamed synovium
from patients with RA has also been demonstrated (28),
and both hematopoietic and nonhematopoietic cells
were implicated as potential sources (29,30), leading to
the proposal that local synthesis of C3 might be impor-
tant in propagating inflammation (30).
Because it is not currently possible to test this
hypothesis in human RA, we did so in the K/BxN mouse




/ mice (31) were maintained locally;
C57BL/6 (B6) mice and B6 mice congenic for the CD45.1
isoform were purchased from The Jackson Laboratory (Bar
Harbor, ME). Animals were maintained under specific
pathogen–free conditions, and all procedures were performed
in accordance with Institutional Animal Care and Use
Committee–approved protocols ARCM-03204 and ARCM-
03912.
Bone marrow chimeras. Recipient mice were lethally
irradiated (6.5 Gy administered twice, 6 hours apart) and
reconstituted intravenously with unfractionated bone marrow
cells (BMCs) freshly obtained from the femurs of donor mice.
Staining for the CD45.1 and CD45.2 isoforms on peripheral
blood leukocytes (PBLs) showed that 95% of PBLs were of
donor origin. Circulating C3 was measured by enzyme-linked
immunosorbent assay (ELISA) and correlated perfectly with
the capacity of the recipient to synthesize C3 (26). Chimeric
animals were tested for arthritis susceptibility 6–12 weeks after
reconstitution.
Parabiotic mice. Wild-type (WT) mice were lethally
irradiated (10 Gy) immediately prior to parabiosis surgery. As
described previously (32,33), animals were anesthetized and
the skin incised from elbow to knee on one side. The elbows
and knees of a pair of mice were sutured together through the
musculature, then the skin incision was stapled and sutured
such that the animals were joined by the dorsal and ventral
skin. Parabionts were given parenteral analgesia for 2 days and
trimethoprim/sulfamethoxazole in the drinking water for 2
weeks. In a pilot experiment using pairs of WT mice mis-
matched for CD45 isoforms, leukocytes from the nonirradiated
partner were readily detectable in the irradiated partner by 7
days after surgery and comprised 90% of the circulating
Figure 1. Arthritis susceptibility in chimeric mice. A, All combina-
tions of wild-type (WT) or C3
/ donors and recipients were used.
Recipients were lethally irradiated, then reconstituted with unfraction-
ated bone marrow cells. Five to 12 weeks after bone marrow reconsti-
tution, mice were injected with 0.15 ml K/BxN mouse serum twice, 2
days apart. B, Arthritis was evaluated qualitatively by clinically assess-
ing the severity in all 4 paws and quantitatively by measuring the
thickness of the right ankle. Values are the mean  SEM for 4 mice
per group (WT cells into C3
/ mice and C3
/ cells into WT mice;
P  0.05) or the mean and range for 2 mice per group (C3
/ cells into
C3
/ mice and WT cells into WT mice). Very similar results were
obtained in a second experiment that included 2 mice per group
(C3
/ cells into WT mice and WT cells into C3
/ mice).
CIRCULATING C3 IN A MOUSE MODEL OF ARTHRITIS 2969leukocytes. Parabionts were tested for susceptibility to arthritis
5 weeks after surgery.
Arthritis induction. K/BxN mice were bred as de-
scribed previously (34). Serum was collected at 7 weeks of age
and stored at 20°C. Serum was injected intraperitoneally by
our standard protocol (14), as follows: 0.15 ml on day 0 and
again on day 2. The 4 paws were assessed by the clinical score
(0–3-point scale for each paw, where 0  no swelling, 1 
either swelling confined to 1 or 2 digits or mild swelling of the
larger structures, 3  severe arthritis involving the wrist or
ankle but extending along the dorsum of the paw to the bases
of the digits, and 2  intermediate severity [score between 1
and 3]). In addition, thickening of the right ankle (or of the
unconstrained ankle in parabiotic mice) was measured using a
precision caliper (Kafer dial thickness gauge with flat anvils;
Long Island Indicator Service, Hauppauge, NY). Disease was
routinely evaluated twice per week.
Histologic assessment and immunofluorescence stain-
ing. For frozen sections, the skin over an ankle was removed
immediately after the animal was killed, and a piece of tissue
10 mm long encompassing the ankle and midfoot joints was
immersed in Tissue-Tek OCT medium (Sakura Finetek, Tor-
rance, CA), flash-frozen in dry ice/ethanol, and stored at
80°C until sectioned. Ankles were sectioned, without prior
decalcification, using a tape transfer method (Instrumedics,
Hackensack, NJ), as described previously (1,16). Sections were
stored at 20°C until used, at which time they were fixed for 5
minutes in acetone at 4°C, briefly allowed to dry, rehydrated
with phosphate buffered saline (PBS) for 15 minutes, blocked
with PBS containing 2% bovine serum albumin (BSA) and
0.1% Tween 20 for 45 minutes, stained with fluorescein-
labeled antibody to C3 (F[ab]2 goat anti-mouse C3; ICN
Biochemicals, Irvine, CA), diluted 1:200 in PBS/0.1% Tween
20 for 60 minutes, then washed 3 times with PBS/Tween 20
before placing coverslips using Gel/Mount medium (Biomeda,
Foster City, CA).
For paraffin sections, fresh tissue containing the ankle
and midfoot joints was fixed in 4% paraformaldehyde at 4°C
overnight, decalcified with 3 changes of 0.375M EDTA (pH
7.5) at 4°C for 2 weeks, and then processed for paraffin
sectioning and hematoxylin and eosin staining by standard
techniques.
Microscopy was performed using a Zeiss Axioplan 2
instrument equipped with a Spot RT Slider camera (Diagnos-
tic Instruments, Sterling Heights, MI) and IPLab imaging
software (Scanalytics, Billerica, MA).
Measurement of C3. Circulating C3 was measured by
ELISA, as previously described (26).
RESULTS
A requirement for C3 synthesis by radioresistant
cells. The role of leukocyte-derived C3 was assessed in
radiation bone marrow chimeras. This experimental
Figure 2. Histopathology of ankle joints, and deposition of C3 in joint tissue. Ankle joints from bone marrow chimeras (as
denoted in Figure 1A) that had been injected with K/BxN mouse serum were processed for paraffin sectioning and stained
with hematoxylin and eosin (H&E), or were processed for frozen sectioning and stained with fluorescein-labeled antibodies
to C3. Arrows indicate linear staining on the cartilage surface. Nonlinear staining in the same sections represents deposition
in the synovium and subsynovial connective tissue. WT  wild-type. (Original magnification  100 for H&E-stained
sections;  200 for sections stained with fluorescein-labeled antibodies to C3.)
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mouse’s hematopoietic cells with cells from a donor
mouse, whereas nonhematopoietic cells remain of host
origin. Thus, WT or C3-deficient recipients were lethally
irradiated, then reconstituted with unfractionated bone
marrow cells from either WT or C3
/ donors (Figure
1A).
Arthritis development after K/BxN serum trans-
fer, whether evaluated by a clinical index or by ankle
measurement, correlated perfectly with the ability of the
recipients’ radioresistant cells to produce C3 (Figure
1B). Furthermore, when 2 mice from each of the critical
groups (C3
/ BMCs into WT mice, and WT BMCs into
C3
/ mice) continued to receive injections of K/BxN
serum for a total of 4 weeks and arthritis was evaluated
until day 42, the WT recipients continued to show severe
inflammation, while disease never developed in the
C3-deficient recipients (results not shown).
Histopathologic assessment of ankle joints con-
firmed the clinical impression of the presence or absence
of inflammatory arthritis with the typical features of a
dense mononuclear cell infiltrate of the subsynovial
connective tissue, neutrophilic joint effusion, loss of
cartilage, and marginal erosion of bone (Figure 2).
According to immunofluorescence staining, arthritic an-
kles from WT recipients had prominent deposits of C3
Figure 3. Arthritis susceptibility in parabiotic mice. A, Noncirculating
parenchymal cells can produce C3 only in the wild-type (WT) partner.
C3 cannot be produced by hematopoietic cells derived from either
partner: the WT mouse lacks endogenous hematopoietic cells due to
the irradiation, while the C3
/ partner is genetically deficient in C3
production by all cell types. Circles represent repopulation of the
hematopoietic lineages in the irradiated mouse by hematopoietic cells
from the C3
/ partner. C3 synthesized in the WT partner circulates
freely through the shared vasculature into the C3-deficient partner. B,
Joined mice were injected with 0.15 ml K/BxN mouse serum (each
partner) twice, 2 days apart, at least 5 weeks after parabiosis surgery.
Arthritis severity in each partner is expressed as the maximum increase
in thickness of the unconstrained ankle (	 mm) and as the clinical
index (CI) in all 4 paws (maximum severity  12). Note that the 2 mice
in pair 4 had undetectable arthritis in the measured joint but unam-
biguous arthritis in the other paws, resulting in discrepancies between
the change in ankle thickness and the clinical score. Arthritis was
somewhat less severe in both partners than is typical for B6 mice,
probably due to variability in arthritogenicity of K/BxN serum, because
4 B6 mice treated concomitantly also developed relatively mild disease
(maximum CIs  2, 5, 6, and 9, respectively). In any case, the
paw-to-paw variation seen in these experiments (as indicated by
discrepancies between the overall CI and the measurement of 1 ankle
in several mice) and the absence of arthritis in 1 mouse are typical of
what we have seen previously in other settings in which arthritis
severity is decreased, such as in relatively resistant mouse strains or
with use of smaller-than-usual amounts of serum. R  rads.
Figure 4. Circulating C3 deposition in arthritic joints. Two weeks
after induction of arthritis in parabiotic mice, tissue containing the
ankle and midfoot joints was processed for frozen sections, which were
then stained with fluorescein-labeled antibodies to C3. Para-B6–
irradiated  lethally irradiated wild-type (WT) partner. Para-C3
/ 
C3
/ partner (as denoted in Figure 3A). Arrows denote staining of
cartilage surfaces. Other areas of staining represent synovial and
subsynovial deposits. An ankle from a B6 mouse that did not receive
K/BxN mouse serum showed no staining (results not shown), similar to
the lack of staining observed in the negative control mouse (original
magnification  100).
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the nonarthritic ankles from C3
/ recipients did not
(Figure 2). In short, production of C3 by leukocytes was
not required for K/BxN serum–induced arthritis, even
with prolonged administration of arthritogenic serum.
No need for C3 synthesis by joint-resident cells.
The next question was whether C3 had to be produced
by radioresistant cells locally within the joint, or whether
it could be made by parenchymal cells at distant sites
and transported to the joints via the circulation. There-
fore, we generated mice whose joint-resident cells could
not synthesize C3 but whose circulation carried C3 that
had been synthesized by cells distant from the joint.
C3-deficient mice were surgically joined with WT ani-
mals immediately after the latter had been subjected to
lethal irradiation in order to ablate circulating blood
cells. As illustrated in Figure 3A, the irradiated WT
partner in these pairs harbored parenchymal cells that
produce C3 and introduce it into the circulation, but
lacked hematopoietic cells that might produce C3. The
C3
/ partner lacked C3 synthesis by both parenchymal
and hematopoietic cells but would be exposed to C3
through its circulation due to anastomosis with the
circulation of the WT partner (Figure 3A). Measure-
ment of circulating C3 confirmed equal concentrations
of C3 in both partners, at levels 25% of those seen in
B6 mice (results not shown). Upon transfer of K/BxN
serum, clear manifestations of inflammatory arthritis
were observed in 4 of the 5 C3
/ partners and all 5 of
the irradiated WT partners (Figure 3B). Immunofluo-
rescence staining of ankle joints confirmed that C3 was
prominently deposited on the cartilage surface and in
the synovium, even in animals whose only source of C3
was through the circulation (Figure 4).
DISCUSSION
Circulating C3, produced by parenchymal cells
distant from the joint, is both necessary and sufficient
for induction of disease in the K/BxN mouse model of
antibody-mediated arthritis. The serum-transfer system
allowed us to focus specifically on the role of C3 in the
inflammatory effector phase, after high levels of auto-
antibodies had been produced. It remains possible that
C3 made either by leukocytes or by joint-resident paren-
chymal cells plays an important role in the initiation
phase of autoimmunity, or that these 2 sources make a
nonessential contribution to the effector process.
It is reasonable to propose that C3 plays a role in
human RA similar to that in the K/BxN serum-transfer
system, particularly in the early stages of inflammation
or in the reactivation of acute inflammation in previ-
ously quiescent joints. Although the specific autoanti-
body responsible for arthritis in the K/BxN mouse model
is observed in only a minority of patients with RA (35),
particularly in those with Felty’s syndrome or other
extraarticular manifestations (36,37), there is now con-
siderable evidence supporting the pathogenicity of au-
toantibodies in RA. First, the B cell–depleting monoclo-
nal antibody rituximab is highly effective in treating
many patients with RA (38). Second, a newly described
mouse model links an RA-specific autoantibody (anti–
citrulline-containing protein) to murine arthritis (39).
The role of complement has not yet been assessed in this
context, but findings made previously in other models
are likely to remain relevant to RA; that is, the ability of
diverse autoantibody responses to generate pathology
resembling RA in mice (40) indicates a general sensitiv-
ity of joints to antibody-mediated inflammation and
supports the generalizability of the principles deter-
mined using the K/BxN mouse model and other models.
The hypothesis that local C3 production is impor-
tant in RA arose from the finding that more C3 is
produced in rheumatoid synovium than in osteoarthritic
synovium, as determined qualitatively or quantitatively
using in situ hybridization to detect messenger RNA
(mRNA) for C3 (28,30). Subsequently, several microar-
ray analyses of synovial gene expression in either human
patients or rodent models have yielded conflicting data
on this point, sometimes showing an increase in synthe-
sis of C3 (41,42) and sometimes not showing such an
increase (43–45). Importantly, we also detected mRNA
for C3 in mouse synovium by both complementary DNA
microarray and quantitative polymerase chain reaction
(data not shown), although we did not observe an
increase as arthritis unfolded.
The mechanism and kinetics by which circulating
C3 gains access to joints are uncertain but not difficult to
envision. Because the synovial “membrane” (function-
ally, a combination of the subsynovial vasculature and
the synovial lining) is rather permeable at baseline,
roughly in inverse proportion to the mass of the macro-
molecule (46,47), and because C3, at 185 kd, is not
extremely large, it would be expected that an abundant
circulating protein of this size would have some passive
access to normal synovial fluid. Indeed, although we are
not aware of any reports in which C3 has been measured
in normal synovial fluid, it has been readily detected in
human osteoarthritic joint effusions at concentrations
similar to those seen in RA, i.e., 0.2–0.5 mg/ml (48,49).
The reason that concentrations in RA are not
higher is probably related to local consumption (4–7,48),
2972 MONACH ET ALbecause inflamed synovium otherwise loses its size-
selective filtration and becomes about equally perme-
able to all macromolecules (46). Even if some increase in
synovial fluid C3 is required for it to be locally activated
and promote inflammation, increased local vascular
permeability may be a very early feature of inflamma-
tory arthritis. For example, studies in the K/BxN mouse
serum-transfer model have shown that IgG-containing
immune complexes selectively increase the permeability
of periarticular vessels to IgG itself (50) and to a higher
molecular weight (400 kd) tracer (51). Interestingly,
complement is not required for this early vascular per-
meability (51); therefore, further research on the role of
complement in this model will likely focus on down-
stream events, such as the role of complement receptors,
particularly C5aR, on different populations of inflam-
matory cells.
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